Back

Clinical pharmacology of AZD9977, a novel, selective mineralocorticoid receptor (MR) modulator without K+-sparing properties

3 September 2019 (12:40 - 13:30)
Organised by:
Congress Presentation Part of: Cardiovascular pharmacotherapy Aldosterone Antagonists ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Andrew Whittaker

AstraZeneca, Gothenburg (Sweden)

6 More presentations in this session

Presentation thumbnail
Research Network in Africa (RNA): quality assessment of antihypertensive generic drugs in 10 African countries
Doctor D. Macquart de Terline (Paris, FR)
Abstract
Presentation thumbnail
Impact on the prognosis of treatment administrated in the daily clinical practice to patients with myocardial infarction with non-obstructive coronary arteries.
Doctor J. Lopez-Pais (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Trends in indications and outcome in thrombolytic therapy: a retrospective single center study
Doctor M. Engelen (Leuven, BE)
Abstract Slides
Presentation thumbnail
Cardioprotective anti inflammatory effects of empaglifozin in doxorubicin induced cardiotoxicity: the role of leukotriene B4 and interleukin 1
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Risk of qtc interval prolongation among cancer patients treated with tyrosine kinase inhibitors
Slides

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy

The Event

Event poster

ESC Congress 2019

3 September 2019 12:40 CET
You may be interested in
thumbnail
Webinar
MRAs in heart failure: what's old is new again
thumbnail
Congress Presentation
Aldosterone-targeted therapies in hypertension
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources